This transcript has been edited for clarity.
I'm Dr Maurie Markman from Cancer Treatment Centers of America. I privation to sermon a precise absorbing insubstantial that precocious appeared successful the Journal of Clinical Oncology, entitled, "Overall Survival With Maintenance Olaparib astatine a 7-Year Follow-up successful Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial."
Most of you astir apt cognize the results of the SOLO1 study, which appeared successful The New England Journal Medicine a fig of years ago. It demonstrated the precise awesome worth of olaparib attraction therapy successful the abbreviated term, reporting progression-free and wide endurance successful patients with precocious ovarian cancer — again, utilized successful attraction — with a BRCA mutation.
This peculiar paper, however, with a 7-year follow-up, begins to code a precise important question: What astir semipermanent follow-up?
This was a randomized, treble blind, placebo-controlled study. Patients with recently diagnosed precocious ovarian crab who achieved a objective effect and had a documented BRCA mutation, either germline oregon somatic, were randomized to olaparib attraction astatine the completion of platinum-based chemotherapy oregon placebo.
Placebo oregon olaparib could beryllium continued up to a maximum of 2 years. Some patients had the opportunity, with the statement of the main investigator, of longer than 2 years, but fundamentally 2 years of attraction therapy with olaparib oregon placebo.
This question of semipermanent follow-up endurance was addressed successful the paper. The median duration of attraction with olaparib connected this proceedings was 24.6 months, arsenic anticipated, and was 13.9 months with placebo. The median follow-up of this diligent colonisation was 88 months, which is longer than 7 years.
The full illustration size of the olaparib-treated patients was 260, and of the placebo-treated patients, 131. The bottommost enactment is that astatine a 7-year follow-up, 67% of the patients who received olaparib were live vs 46.5% of the placebo-treated patients. Again, this was a attraction phase. There was fundamentally a 20% higher implicit fig of patients who were live who received olaparib vs placebo.
Looked astatine different way, astatine this peculiar constituent successful time, astatine 7-year follow-up, 45.3% of patients who had received olaparib were live and had not received a consequent attraction regimen. In different words, they were live and they were inactive connected follow-up without getting different anticancer therapy.
So 45.3% — astir fractional — of the patients who received olaparib had not received immoderate further therapy vs 20.6% of patients receiving placebo who were live and had not received immoderate further therapy. That is, the placebo-treated patients had fractional the probability of remaining [alive] without immoderate further therapy. Among the olaparib-treated patients, again, astir fractional had nary further therapy astatine a follow-up of 7 years.
In addition, and precise importantly, the study, with semipermanent follow-up, showed a precise debased hazard for myelodysplastic syndrome oregon acute leukemia, which was a interest with PARP inhibitors. There were nary caller primaries oregon information concerns with this semipermanent follow-up.
This study, SOLO1, again emphasized this point. Long-term follow-up endurance information demonstrated the worth of attraction olaparib aft an archetypal effect to platinum-based chemotherapy successful women with a BRCA mutation. There is nary question that determination is large worth successful this diligent population.
For those of you funny successful this taxable and the absorption of ovarian cancer, oregon patients oregon household who are funny successful this peculiar question, I notation you to this precise important study, precocious published successful the Journal of Clinical Oncology. Thank you for your attention.
Maurie Markman, MD, is president of medicine and subject astatine Cancer Treatment Centers of America successful Philadelphia. He has much than 20 years of acquisition successful crab attraction and gynecologic oncology research.
Follow Medscape connected Facebook, Twitter, Instagram, and YouTube
English (US)